Immune drugs are widely used in GC treatment, which inhibit JAK-STAT signaling can achieve both targeted blockade and avoid creating an immunosuppressive environment, so JAK and START inhibitors have good application prospects in cancer research, and combined immunosuppressants provide new therapeutic ideas for GC patients (Kiu and Nicholson, 2012; Li et al., 2016). This evidence concerns the gene SOAT1 and cancer.